EANS-News: Epigenomics' Lincensee ARUP to Present Clinical Data on Colorectal Cancer Blood Test at US Cancer Conference

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information/Molecular diagnostics

Berlin and Seattle, October 18, 2010 (euro adhoc) - ARUP
Laboratories, Salt Lake City, UT, USA, a licensee of Epigenomics,
will present clinical data validating ARUP's laboratory-developed
test for the detection of methylated Septin9 DNA in blood plasma at
the ASCO-NCI-EORTC 2010 Annual Meeting on Molecular Markers in Cancer
that starts today in Hollywood, FL, USA.

Karen A. Heichman, PhD, Vice President Oncology Technology
Development & Licensing at ARUP will present the poster entitled:
"Use of the Septin9 methylated DNA biomarker to detect cancer in the
blood of colorectal cancer patients" in a Poster Discussion Session
on Tuesday, October 19, 2010.

ARUP licensed the Septin9 biomarker for the early detection of
colorectal cancer in a simple blood draw from its discoverer
Epigenomics AG, the Berlin and Seattle based cancer diagnostics
company. ARUP launched a laboratory-developed test for the detection
of this biomarker in blood plasma in July 2010.

Epigenomics will report on the clinical data presented by ARUP in a
press release on Wednesday, October 20, 2010.

- Ends -

Notes to the Editor

Poster Presentation Details

Conference: ASCO-NCI-EORTC 2010 Annual Meeting on Molecular Markers
in Cancer Venue: Westin Diplomat Hotel, Hollywood, FL, USA Abstract
ID: 71 Abstract Title: Use of the Septin 9 methylated DNA biomarker
to detect cancer in the blood of colorectal cancer patients.
Presenter: Karen A. Heichman, PhD, VP Oncology Technology Development
& Licensing Session: General Poster Session B Tuesday,
October 19, 2010; 12:15 - 1:50 pm and 6:00 - 7:00 pm

About the Septin9 Biomarker and Colorectal Cancer Blood Tests

The Septin9 biomarker is at the core of the world's first in vitro
diagnostic and laboratory-developed blood tests for the early
detection of colorectal cancer commercialized by Epigenomics (Epi
proColon), and its partners Abbott Molecular (mS9), Quest Diagnostics
(ColoVantage?), and ARUP Laboratories (Methylated Septin9 Test) in
Europe, Asia/Pacific, and the U.S. The tests all detect cell-free
methylated DNA of the Septin9 gene shed into the blood stream by
colorectal tumors. In numerous studies, Epigenomics and its partners
have demonstrated that the detection of the Septin9 biomarker in
blood plasma correlates with the presence of colorectal cancer and
thus can be used as an aid in the detection of this common cancer.
These studies include the successfully completed PRESEPT Study, a
prospective evaluation of the Septin9 biomarker in a cohort of almost
8,000 individuals representative of a typical screening population.

Lack of patient adherence to screening recommendations is the biggest
hurdle to an effective screening for colorectal cancer. Experts
believe that a blood test that is more convenient for the patients
than stool tests and colonoscopy could help to get more people
screened than are currently and thus be of medical and health
economic benefit.

About Epigenomics

Epigenomics is a molecular diagnostics company with a focus on the
development of novel products for cancer. Using DNA methylation
biomarkers, Epigenomics' tests on the market and in development aim
at detecting cancer before symptoms occur and thereby potentially
reducing mortality from this disease.

Epigenomics' product portfolio contains the CE-marked IVD test Epi
proColon, the world's first regulatory cleared molecular diagnostic
test for the detection of colorectal cancer in blood that is based on
the biomarker Septin9, and further proprietary DNA methylation
biomarkers and IVD products at various stages of development and
commercialization for colorectal, lung and prostate cancer. For
development and global commercialization of IVD test products,
Epigenomics pursues a dual business strategy in which direct
commercialization of proprietary diagnostic test products is combined
with non-exclusive licensing to diagnostic industry players with
broad customer access. Strategic diagnostics industry partners
include Abbott Molecular, Sysmex Corporation, Quest Diagnostics
Incorporated, and ARUP Laboratories, Inc. for diagnostics test
products and services, and QIAGEN N.V. for sample preparation
solutions and research products.

The company is headquartered in Berlin, Germany, and has a wholly
owned subsidiary, Epigenomics Inc., in Seattle, WA, USA. For more
information, please visit Epigenomics' website at HYPERLINK
"http://www.epigenomics.com"www.epigenomics.com.

Epigenomics' legal disclaimers. This communication expressly or
implicitly contains certain forward-looking statements concerning
Epigenomics AG and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any
future results, performance or achievements expressed or implied by
such forward-looking statements. Epigenomics AG is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise.

The information contained in this communication does not constitute
nor imply an offer to sell or transfer any product, and no product
based on this technology is currently available for sale by
Epigenomics in the United States of America. The analytical and
clinical performance characteristics of any product based on this
technology which may be sold at some future time in the USA have not
been established.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Epigenomics AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Dr. Achim Plum

Sen. VP Corporate Development

Epigenomics AG

Tel: +49 30 24345 368

achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade